摘要
目的:评价沙美特罗/氟替卡松复合干粉吸入剂(SFC)与布地奈德干粉吸入剂(BUD)治疗哮喘的成本-效果。方法:在SFC50/100μg、bid与BUD400μg、bid治疗386例哮喘患者的多中心、随机临床对照试验基础上回顾性收集资料,进行成本-效果分析,效果指标采用成功治疗周、无症状日和未受累日;成本指标采用直接医疗服务成本。结果:SFC组的平均每日治疗成本(15.6元)略高于BUD组(13.8元),但SFC组每成功治疗周、无症状日和未受累日成本分别为166.5元、33.4元和41.2元,均低于BUD组(188.6元、50.6元和66.1元);SFC组相对于BUD组的增量成本-效果比分别为每成功治疗周88.7元、每无症状日9.4元和每未受累日10.8元。结论:SFC50/100μg、bid治疗哮喘的成本-效果优于BUD400μg、bid。
OBJECTIVE： To evaluate the cost - effectiveness of salmeterol / fluticasone compound （SFC） and budesonide （BUD） in the treatment of asthma. METHODS： A multicenter randomized controlled clinical trial was performed on 386 asthma cases, who were administered with SFC 50/100μg bid or BUD 400μg bid, data on which were retrospectively collected and then the cost - effectiveness analysis was conducted, the effectiveness was measured in terms of successfully - treated weeks, symptom free days and uninvolved days; The direct healthcare cost was adopted as the cost index. RESULTS： The average daily medical cost of the SFC treatment group （RMB： 15.6 yuan） was a little bit higher than that of the BUD control group （RMB： 13.8 yuan）, but the costs of every successfully - treated week, every symptom- free day and every uninvolved day for SFC group were 166,5yuan, 33.4 yuan and 41.2 yuan, respectively, which were all lower than those of the BUD group （which were 188.6 yuan, 50.6 yuan and 66.1 yuan, respectively）; Incremental cost- effectiveness ratios for every successfully - treated week, per symptom free.day and peruninvolved day for the SFC group were 88.7 yuan，9.4 yuan and 10.8 yuan,respectively vs. the BUD group. CONCLUSION： The results show that the cost- effectiveness of SFC 50/100μg bid is superior to BUD 400μg bid in the treatment of asthma。
出处
《中国药房》
CAS
CSCD
北大核心
2005年第16期1233-1236,共4页
China Pharmacy
